Amsidine (amsacrine) / Kyowa Kirin - LARVOL DELTA

DEXAML-03: Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - P3 | N=73 | Terminated | Sponsor: University Hospital, Toulouse | N=142 ➔ 73 | Trial completion date: Dec 2025 ➔ May 2024 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2025 ➔ May 2024; Despite a recruitment target that was not met, we managed to achieve more than 50% of inclusions and 33% of deaths, enabling us to carry out an initial analysis of the primary endpoint

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

IMPROVED LONG TERM SURVIVAL OF PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES AFTER UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION WITH SEQUENTIAL CONDITIONING – ADDITION OF VENETOCLAX PROLONGS RFS (EBMT 2025) - "The FLAMSA- (Fludarabine/Amsacrine/Ara-C) protocol, which has already been modified multiple times, was last amended by adding venetoclax, an inhibitor of B-Cell Lymphoma-2 that has synergistic effects to chemotherapy, without increasing non-hematologic toxicity... In this retrospective survey, we identified 53 patients (median age 61 years, range 20 - 74, 20 female) with myeloid malignancies (43 MDS, 7 AML, 3 CMML) who had received either FLAMSA (27 patients) or FLAMSAClax (26 patients) + Alkylator (Melphalan or Treosulfan) based between 2018 and 2023...ATG was used in 40 (75.5%) and post-transplant cyclophosphamide (ptCy) in 8 patients (15.1%) in addition to GvHD prophylaxis with Tacrolimus or CSA and MMF... Upfront allografting in patients with high-risk myeloid malignancies can achieve overall survival rates of around 80% at 2 years while the addition of Venetoclax to FLAMSA + Alkylator prolongs relapse-free survival. With median time to relapse of 691 days after..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Oncology • Transplantation • BCL2

SEQUENTIAL FLAMSA-FB CONDITIONING IMPROVES PFS IN UNTREATED MDS PATIENTS UNDERGOING ALLOGENEIC HSCT COMPARED TO ALTERNATIVE REGIMENS (EBMT 2025) - "Forty-five received FLAMSA and 61 alternative conditioning: TB (n=30), FB (n=16), or Treo-Flu (n=15).FLAMSA: Fludarabine 30 mg/m²/day (total 120 mg/m²), amsacrine 100 mg/m²/day (total 400 mg/m²), and cytarabine 1 g/m²/day (total 4 g/m²) on days -11 to -8, followed by a 3-day break. Then busulfan 6.4 mg/kg (days -4 to -3) plus fludarabine 30 mg/m² (total 60 mg/m²) for FLAMSA-FB or busulfan 6.4 mg/kg for FLAMSA-Bu.TB: Thiotepa 5 mg/kg/day (total 10 mg/kg; days -6, -5) and busulfan 3.2 mg/kg/day (total 6.4 or 9.6 mg/kg; days -4, -3 for >60 years or days -4 to -2 for ≤60 years).Treo-Flu: Treosulfan 12 g/m²/day (total 36 g/m²; days -6 to -4) and fludarabine 30 mg/m²/day (total 150 mg/m²; days -6 to -2).FB: Busulfan 6.4 mg/kg (days -7 to -5) and fludarabine 30 mg/m²/day (total 150 mg/m²; days -7 to -3)... In untreated MDS patients undergoing allo-SCT, the sequential FLAMSA-FB regimen improved PFS compared..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Leukemia • Myelodysplastic Syndrome

SEQUENTIAL FLAMSA-FB CONDITIONING IMPROVES PFS IN UNTREATED MDS PATIENTS UNDERGOING ALLOGENEIC HSCT COMPARED TO ALTERNATIVE REGIMENS (EBMT 2025) - "Forty-five received FLAMSA and 61 alternative conditioning: TB (n=30), FB (n=16), or Treo-Flu (n=15).FLAMSA: Fludarabine 30 mg/m²/day (total 120 mg/m²), amsacrine 100 mg/m²/day (total 400 mg/m²), and cytarabine 1 g/m²/day (total 4 g/m²) on days -11 to -8, followed by a 3-day break. Then busulfan 6.4 mg/kg (days -4 to -3) plus fludarabine 30 mg/m² (total 60 mg/m²) for FLAMSA-FB or busulfan 6.4 mg/kg for FLAMSA-Bu.TB: Thiotepa 5 mg/kg/day (total 10 mg/kg; days -6, -5) and busulfan 3.2 mg/kg/day (total 6.4 or 9.6 mg/kg; days -4, -3 for >60 years or days -4 to -2 for ≤60 years).Treo-Flu: Treosulfan 12 g/m²/day (total 36 g/m²; days -6 to -4) and fludarabine 30 mg/m²/day (total 150 mg/m²; days -6 to -2).FB: Busulfan 6.4 mg/kg (days -7 to -5) and fludarabine 30 mg/m²/day (total 150 mg/m²; days -7 to -3)... In untreated MDS patients undergoing allo-SCT, the sequential FLAMSA-FB regimen improved PFS compared..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Leukemia • Myelodysplastic Syndrome

LONG-TERM SURVIVAL AFTER SEQUENTIAL CONDITIONING WITH FLAMSA AND TOTAL BODY IRRADIATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (EBMT 2025) - "Major improvement for deep remission was observed in Philadelphia positive (BCR-ABL) as well as negative b-precursor ALL with the introduction of tyrosine kinase inhibitors as well as Blinatumomab and Inotuzumab...Of Patients with B-ALL 33% were Philadelphia chromosome positive.In this subgroup analysis we report the outcome of 28 patients (14 B-ALL, 14 T-ALL, 71% male, 29% female, median age at transplant 29 years, range 17-61) who received a sequential conditioning regimen containing Fludarabin, Amsacrine, high-dose Cytarabine (FLASMA) combined with Total Body Irradiation (TBI) of 8-12 Gy... Even in high-risk groups and especially in patients with T-ALL sequential conditioning containing FLAMSA and TBI results in remarkable long-term survival with a manageable toxicity profile."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • ABL1 • BCR

LONG-TERM SURVIVAL AFTER SEQUENTIAL CONDITIONING WITH FLAMSA AND TOTAL BODY IRRADIATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (EBMT 2025) - "Major improvement for deep remission was observed in Philadelphia positive (BCR-ABL) as well as negative b-precursor ALL with the introduction of tyrosine kinase inhibitors as well as Blinatumomab and Inotuzumab...Of Patients with B-ALL 33% were Philadelphia chromosome positive.In this subgroup analysis we report the outcome of 28 patients (14 B-ALL, 14 T-ALL, 71% male, 29% female, median age at transplant 29 years, range 17-61) who received a sequential conditioning regimen containing Fludarabin, Amsacrine, high-dose Cytarabine (FLASMA) combined with Total Body Irradiation (TBI) of 8-12 Gy... Even in high-risk groups and especially in patients with T-ALL sequential conditioning containing FLAMSA and TBI results in remarkable long-term survival with a manageable toxicity profile."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • ABL1 • BCR

Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups (ASH 2024) - P2/3 | "In case of CR, the HSCT protocol strategy recommended a Seq FLAMSA (Fludarabine 30 mg/m2, high-dose cytarabine 2 g/m2, and amsacrine 100 mg/m2) followed by a RIC regimen (Busulfan 6.4 mg/kg and cyclophosphamide 100 mg/kg) from matched sibling donor (MSD), 10/10 (MUD) or 9/10 (MMUD) unrelated donors. GvHD prophylaxis consisted in rabbit ATG 5 mg/kg with CsA plus MMF...Conclusion : The 5-yrs OS of 41.2% compares favorably with published results. While a Seq regimen did not improve HSCT outcomes, best results were obtained in younger pts with adv risk AML in CR at time of HSCT irrespective of graft source for those transplanted less than 6 months after AML diagnosis."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial (ASH 2024) - "Subjects with AML in CR1 (n=45) or CR2 (n=47) were conditioned with a myeloablative regiment consisting of Busulfan (age adjusted i.v. dosing : 3.2 – 4,8 mg/kg BW on days -7 through -4), Cyclophosphamide (60mg/kg i.v. on days -3 and -2), and Melphalan (140 mg/m2 i.v. on day -1) (BuCyMel). Graft-versus-Host disease (GvHD) prophylaxis was cyclosporine (CSA) and short-term methotrexate...Patients with poor response to AML induction therapy (n=48) were stratified to receive a reduced-intensity regimen consisting of a cytoreductive block with Fludarabine (30mg/m2/d i.v.), Amsacrine (100 mg/m2/d i.v.), and Cytarabine (2g/m2/d i.v.) (FLAMSA) on days -12 through -9, immediately followed by 4 Gy TBI on day -5 and Cyclophosphamide (60 (unrelated)/40 (related) mg/kg/day i.v.) on days -4 through -3...CONCLUSION : With improving HLA-typing technology, OS and CI of chronic and acute GvHD II-IV are identical after MUD- and MSD-transplantation for pediatric AML, if ATLG is added for..."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Pediatrics

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL (clinicaltrials.gov) - P2/3 | N=745 | Completed | Sponsor: Universitätsklinikum Hamburg-Eppendorf | Active, not recruiting ➔ Completed

Trial completion • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Pediatrics

No improvement in outcomes by sequential conditioning in allogeneic stem cell transplantation of CMML patients (DGHO 2024) - " This retrospective study from University Medical Center Hamburg, Germany, compared SCT outcomes in CMML patients across three conditioning regimes: Thiotepa-Busulfan (TB), Sequential FLAMSA-Busulfan Fludarabine (FLAMSA-FB), and Treosulfan-Fludarabine (Treo-Flu)...FLAMSA-FB: Fludarabine (30 mg/m 2 ), amsacrine (100 mg/m 2 ), cytarabine (1 g/m 2 ) from days -11 to -8, followed by Busulfan and Fludarabine on days -4 and -3... Our study suggests that sequential conditioning with FLAMSA-FB does not improve Transplant outcomes in patients undergoing allo-SCT for CMML."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Immunology • Transplantation

Is AML Remission Induction Prior to alloHCT Necessary? (ICBMT 2024) - "To test salvage chemotherapy prior to alloHCT, patients aged between 18 and 75 years with AML and poor response after first induction or untreated first relapse and available HLA-compatible donor were randomized 1:1 to remission induction (RIST) with high-dose cytarabine plus mitoxantrone or immediate alloHCT with sequential conditioning after disease control (DisC)...In the DisC arm sequential conditioning regimens combining remission induction with fludarabine-modulated high-dose cytarabine plus amsacrine or with high-dose melphalan combined with reduced-intensity conditioning with fludarabine plus total body irradiation or alkylator-based reduced-intensity conditioning were favored but the dose-intensity was adapted to patient's fitness...Smarter bridging concepts with targeted drugs are warranted especially for adverse risk AML and need to be tested in RCTs to demonstrate survival advantage after alloHCT. Together with the profound impact of AML genetic risk on..."

Clinical • Acute Myelogenous Leukemia

LIPOSOMAL CYTARABINE AND DAUNORUBICIN (CPX-351) VERSUS INTENSIVE INDUCTION CHEMOTHERAPY IN PATIENTS WITH THERAPY-RELATED AML OR AML WITH MDS-RELATED CHANGES: A COMPARATIVE HOVON-SAKK ANALYSIS (EHA 2024) - "The HOVON 7+3 regimen for patients aged ≥60 years consists of 2induction cycles with cytarabine 200 mg/m2/day for 7 days plus daunorubicin 45 or 60 mg/m2/day oridarubicin 12 mg/m2/day for 3 days in cycle 1, and cytarabine 1000 mg/m2 twice daily for 6 days anddaunorubicine 60 mg/m2/day or amsacrine 120mg/m2/day for 3 days in cycle 2...Per protocols, patientsreceived no prior treatment for AML except for hydroxyurea... Comparing the CPX-351 trial cohort with a selected HOVON 7+3 cohort consisting of higher doses ofcytarabine in t-AML or AML-MRC patients suggests higher CR/CRi rates and similar OS with the HOVON 7+3induction regimen."

Clinical • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Disorders • Myelodysplastic Syndrome

GENETIC BIOMARKERS PREDICTING PROGNOSIS IN PATIENTS WITH CHOLANGIOCARCINOMA; A BIOINFORMATICS APPROACH STUDY (DDW 2024) - "After reviewing ENRICHER dataset these genes are potential targets for certain pharmacologic options such as Cladribine Amsacrine Etoposide and Fulvestrant. Identification of certain genes by bioinformatic approach can optimize prognostication in patients with CC. It also shed light into mechanistic pathways and suggest potential pharmacologic targets for management of CC."

Biomarker • Clinical • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • ANLN • ER • PLAU

Structural insights into the transporting and catalyzing mechanism of DltB in LTA D-alanylation. (PubMed, Nat Commun) - "We further visualize DltB in an apo form, in complex with DltC, and in complex with its inhibitor amsacrine (m-AMSA)...The tetrameric organization of DltB provides a scaffold for catalyzing D-alanyl transfer and regulating the channel opening and closing. Our findings unveil DltB's dual function in the D-alanylation pathway, and provide insight for targeting DltB as a anti-virulence antibiotic."

Journal • Infectious Disease

Unraveling the Molecular Complexity of Adenoid Cystic Carcinoma (ACC): A Comprehensive Exploration of Hub Genes, Protein-Protein Interaction (PPI) Networks, microRNA (miRNA) Involvement, and Drug-Gene Interactions (DGIs). (PubMed, Cureus) - "The dysregulation of microRNAs and transcription factors adds complexity to ACC's molecular profile. Exploration of drug-gene interactions reveals promising therapeutic strategies, involving FDA-approved drugs such as amsacrine and rucaparib, providing avenues for personalized interventions."

Journal • Adenoid Cystic Carcinoma • Oncology • BUB1 • CDK1 • E2F1 • KIF11 • MIR138 • MIR7 • TP53

SEQUENTIAL CONDITIONING DOES NOT IMPROVE OUTCOMES OF ALLOGENEIC STEMCELL TRANSPLANTATION IN CMML PATIENTS (EBMT 2024) - " This retrospective study from the Department of Stem Cell Transplantation at the University Medical Center Hamburg, Germany, compared allo-SCT outcomes in CMML patients across three conditioning regimes: Thiotepa-Busulfan (TB), Sequential FLAMSA-Busulfan Fludarabine (FLAMSA-FB), and Treosulfan-Fludarabine (Treo-Flu)...FLAMSA-FB regimen consists of fludarabine (30 mg/m2 ; total dose 120 mg/m2 ), amsacrine (100 mg/m2 ; total dose 400 mg/m 2 ), and cytarabine (1 g/m2 ; total dose 4 g/m 2 ) therapy from days -11 to minus -8, followed by a three-day interval without therapy and Busulfan from day -4 to -2 with a total dose of 6.4mg/Kg and Fludarabine on day -4 and -3 (30 mg/m2, total dose 60mg/m 2 ).Treo-Flu regimen consisted of Treosulfan (12 g/m2 , total dose 36 mg/m2 ) on days-6 to -4 and fludarabine (30 mg/m2 ; total dose 150 mg/m2 ) on days -6 to -2... Our study suggests that sequential conditioning with FLAMSA-FB does not improve Transplant outcomes in patients..."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Immunology • Transplantation

Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH) (ASH 2023) - "In France, lomustine was added to 7+3 in patients >60 years. The most frequent second-line therapy in the whole IC population was salvage chemotherapy with high-dose or intermediate-dose cytarabine or a combination of either of these with anthracycline (daunorubicin, idarubicin, or amsacrine) in France and decitabine or the combination of cytarabine, etoposide and mitoxantrone in the USA. Azacitidine/venetoclax combination was used in second and third line in France and USA and it was the most frequent third-line therapy (35.8%) in France. Patients received IC in combination with targeted therapies (mainly midostaurin) in 18% of the IC population in France and 12.4% of the IC population in the USA...In the REAL-IDH study we observed that treatment patterns in mIDH1 or wild type patients were similar. More specific data is needed regarding the sequencing of treatment regimens and overall outcomes in mIDH1 AML patients."

Clinical • Clinical data • HEOR • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Critical care • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Septic Shock • IDH1

Targeting Loss of the Tumor Suppressor TENT5C in Multiple Myeloma (ASH 2023) - "Inhibitors targeting the cell cycle (roscovitine, apigenin, SP60012) and angiogenesis (amsacrine) were selected for validation and further investigation. Our results indicate a tumor suppressor role of TENT5C in MM, with antiproliferative properties and a susceptibility to spliceosome and NHEJ inhibitors. The HTP screen identified other targets that are currently undergoing validation leading to the identification of the molecular mechanisms underlying this function."

Hematological Malignancies • Multiple Myeloma • Oncology • NT5C • TENT5C

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients (ASH 2023) - " This retrospective study from the Department of Stem Cell Transplantation at the University Medical Center Hamburg, Germany, compared allo-SCT outcomes in CMML patients across three conditioning regimes: Thiotepa-Busulfan (TB), Sequential FLAMSA-Busulfan Fludarabine (FLAMSA-FB), and Treosulfan-Fludarabine (Treo-Flu)...FLAMSA-FB regimen consists of fludarabine (30 mg/m2; total dose 120 mg/m2 ), amsacrine (100 mg/m2; total dose 400 mg/m 2 ), and cytarabine (1 g/m2; total dose 4 g/m 2 ) therapy from days -11 to minus -8, followed by a three-day interval without therapy and Busulfan from day -4 to -2 with a total dose of 6.4mg/Kg and Fludarabine on day -4 and -3 (30 mg/m2, total dose 60mg/m 2 ).Treo-Flu regimen consisted of Treosulfan (12 g/m2 , total dose 36 mg/m2 ) on days-6 to -4 and fludarabine (30 mg/m2; total dose 150 mg/m2 ) on days -6 to -2...Lastly, cumulative incidences of acute GVHD grade II-IV (TB 41%, FLAMSA-FB 35%, Treo-Flu 30%, p=0.75) and all-grade chronic..."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Immunology • Transplantation

The Role of Small Nucleolar RNAs As Putative Biomarkers of Chemoresistance in Pediatric Acute Lymphoblastic Leukemia (ASH 2023) - "05 and absolute log2FC>1) in the high-resistance group for one or multiple drugs: amsacrine (ams, n = 10), etoposide (eto, n = 10), tioguanine (thio, n = 8) and mitoxantrone (mito, n = 1). Importantly, our analysis indicates that the differential expression of snoRNAs in the resistance groups cannot be solely attributed to host gene expression, implying that targeting pathways involving host genes might not be the most effective approach. Rather than concentrating on pathways involving host genes, our results suggest that understanding the mechanisms of action of snoRNAs could provide promising avenues for developing novel therapeutic targets to enhance drug response in pediatric ALL."

Biomarker • Clinical • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Pediatrics • SNHG1

Sequential Allogeneic Stem Cell Transplantation (alloSCT) After Venetoclax (Ven)‑Based Therapy for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Myelodysplastic Syndrome With Excess Blasts 2 (MDS‑EB2) (SOHO 2023) - "Interventions: Prior to sequential alloSCT, patients received: triplet ACTIVE therapy (Ven, low-dose cytarabine, actinomycin D), n=12; FLAMSA (fludarabine, amsacrine, cytarabine) + Ven, n=1; FLAG- Ida (fludarabine, high-dose cytarabine, idarubicin, granulocyte- colony stimulating factor) + Ven, n=1; and decitabine + Ven, n=1. Sequential allotransplantation after Ven-based therapies resulted in short-term remissions and modest OS in this real-life, high-risk R/R AML or MDS-EB2 group."

Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

Molecular insights into drug-induced GDF15 regulation in cancer cells and cardiomyocytes: implications for precision medicine (News-Medical) - "In the present study, researchers...used human-induced pluripotent stem cell-derived (hiPSC)-CMs to examine how drug-induced cardiotoxicity impacts GDF15 expression...GDF15 levels measured for sub-lethal and highest drug concentrations were three-fold increased by DNA-damaging drugs [etoposide, camptothecin, amsacrine, idarubicin, and doxorubicin]...Around 64% of cluster C cell lines were doxorubicin-responsive...Two-thirds of cluster D cell lines had mutations in B-Raf proto-oncogene, serine/threonine kinase (BRAF), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta...Topoisomerase inhibitors (doxorubicin) and DNA-interacting drugs were most potent in inducing GDF15....Overall, the findings indicate that the risk of GDF15 overexpression and cachexia can be minimized through a personalized selection of anti-cancer drugs."

Preclinical • Cachexia

In Silico Screening of Inhibitors of the Venezuelan Equine Encephalitis Virus Nonstructural Protein 2 Cysteine Protease. (PubMed, Viruses) - "Other compounds from the NCATS libraries such as the H1 antihistamine oxatomide (>5-log reduction), emetine, amsacrine an intercalator (NCGC0015113), MLS003116111-01, NCGC00247785-13, and MLS00699295-01 were found to effectively reduce VEEV viral replication in plaque assays...Rates of inactivation by CA074 in the presence of 6 mM CaCl, MnCl, or MgCl were measured with varying concentrations of inhibitor, Mg and Mn slightly enhanced inhibitor binding (3 to 6-fold). CA074 inhibited not only the VEEV nsP2 protease but also that of CHIKV and WEEV."

Journal • Chikungunya • CNS Disorders

Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway. (PubMed, Toxicol Appl Pharmacol) - "Altogether, the results of this study suggest that amsacrine triggers apoptosis in K562 cells by inhibiting BCL2L1 expression through the SIDT2/NOX4/ERK-mediated downregulation of HuR. Furthermore, a similar pathway also explains the cytotoxicity of amsacrine in CML MEG-01 and KU812 cells."

IO biomarker • Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • BCL2 • BCL2L1 • MIR22 • MIR25 • NOX4

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (clinicaltrials.gov) - P1/2 | N=38 | Recruiting | Sponsor: Heinrich-Heine University, Duesseldorf | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Solid Tumor • Transplantation • DEK • IDH1 • IDH2 • KMT2A • KRAS • NF1 • NRAS • NUP214 • PTPN11 • RIT1 • RUNX1 • TP53